Advertisement

Drugs and Chronic Viral Hepatitis

  • Ajay Batra
  • Richard W. Lambrecht
  • Herbert L. Bonkovsky
Part of the Clinical Gastroenterology book series (CG)

Abstract

This is a medicinal age. Indeed, it appears that it has always been so, because human kind, even in antiquity and prehistoric times, appears to have been fascinated with exogenous chemicals and xenobiotics that affect the mind and body. However, advances in therapeutics have been truly remarkable within the past one or two generations. Increasingly, new drugs are being developed, based on biochemical and structural knowledge of specific targets, such as site-directed inhibitors of enzymes in host human beings, or in infectious agents. Other drugs are targeted at specific receptors such as the histamine type- 1 and -2 receptors, the several types of serotonin receptors, and so on.

Keywords

Liver Disease Chronic Hepatitis Chronic Liver Disease Herbal Remedy Chronic Viral Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schenker S, Ralston R, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098–1105.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoyumpa AM, Schenker S. Influence of liver disease on the disposition and elimination of drugs. In: Diseases of the Liver (Schiff L, Schiff ER, eds.), 7th ed. Philadelphia: JB Lippincott 1993. pp. 784–824.Google Scholar
  3. 3.
    Greenblatt DJ, Koch-Weser J. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. Eur J Clin Pharmacol 1974; 7: 259–262.PubMedCrossRefGoogle Scholar
  4. 4.
    Roberts MS, Rumble RH, Wanwimolruk DT, et al. Pharmacokinetics of aspirin and dalicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 1983; 25: 253–261.PubMedCrossRefGoogle Scholar
  5. 5.
    Branch RA. Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease? Hepatology 1987; 7: 772–776.CrossRefGoogle Scholar
  6. 6.
    Murata T, Hideki T, Watanabe S, et al. Enhancement of chronic viral hepatic changes by alcohol intake in patients with persistent HBs-antigenemia. Am J Clin Pathol 1990; 94: 270–273.PubMedGoogle Scholar
  7. 7.
    Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26(Suppl 1): 39S–42S.CrossRefGoogle Scholar
  8. 8.
    MaherJ.Alcoholicliverdisease.In:GastrointestinalandLiverDisease(Sleisenger MH, Fordtran JS, eds.), 6th ed. Philadelphia: Saunders, 1998, pp. 1199–1202.Google Scholar
  9. 9.
    Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety 1997; 17: 47–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis. Dermatologica 1987; 175: 178–182.PubMedCrossRefGoogle Scholar
  11. 11.
    West SG. Methotrexate hepatotoxicity. Rheum Dis Clin NA 1997; 23: 883–914.CrossRefGoogle Scholar
  12. 12.
    Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 88: 1337–1345.Google Scholar
  13. 13.
    Bonkovsky HL, Banner BF, Lambrecht RW, et al. Iron in liver diseases other than hemochromatosis. Sem in Liver Dis 1996; 16: 65–82.CrossRefGoogle Scholar
  14. 14.
    Barton JC, Edwards CQ, eds. Part V of Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge UK: Cambridge University Press, 2000, pp. 229–328.Google Scholar
  15. 15.
    Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatologv 1997; 25: 759–7668CrossRefGoogle Scholar
  16. 16.
    Fong TL, Han SH, Tsai NC, et al. Pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998; 28: 369–374.PubMedCrossRefGoogle Scholar
  17. 17.
    Fontana RJ, Israel J, LeClair P, et al. Iron reduction prior to and during interferon therapy of chronic hepatitis C: results of a multi-center, randomized, controlled trial. Hepatology 2000: 31: 730–736.PubMedCrossRefGoogle Scholar
  18. 18.
    Tsukamoto H, Horne W, Seiichiro K, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995; 96: 620–630.PubMedCrossRefGoogle Scholar
  19. 19.
    Kondili LA, Tosti ME, Szklo M, et al. Relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania. Epidemiol Infect 1998; 121: 391–395.PubMedCrossRefGoogle Scholar
  20. 20.
    Farrell, GC. Drug Induced Liver Disease. Melbourne: Churchill Livingstone, 1994.Google Scholar
  21. 21.
    Horsmans Y, Brenard R, Geubel AP. Short report: interferon-alpha decreases 14Caminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther 1994: 8: 353–355.PubMedCrossRefGoogle Scholar
  22. 22.
    Niwa T, Sato R, Yabusaki Y, et al. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 1999; 29: 1 87–193.Google Scholar
  23. 23.
    Pageaux GP, le Bricquir Y, Berthou F, et al. Effects of interferon-alpha on cytochrome P-450 isoforms I A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10: 491–495.PubMedCrossRefGoogle Scholar
  24. 24.
    Delaporte E, Renton KW. Cytochrome P4501A1 and cytochrome P4501A2 are downregulated at both transcriptional and post-transcriptional levels by conditions resulting in interferon-alpha/beta induction. Life Sci 1997; 60: 787–796.PubMedCrossRefGoogle Scholar
  25. 25.
    Carlson TJ, Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol 1996; 49: 796–801.PubMedGoogle Scholar
  26. 26.
    Hodgson PD, Renton KW. Role of nitric oxide generation in interferon-evoked cytochrome P450 downregulation. Int J Immunopharmacol 1995; 17: 995–1000.PubMedCrossRefGoogle Scholar
  27. 27.
    Moochhala SM, Renton KW. Role for xanthine oxidase in the loss of cytochrome P-450 evoked by interferon. Can J Physiol Pharmacol 1991; 69: 944–950.PubMedCrossRefGoogle Scholar
  28. 28.
    Adachi Y, Yokoyama Y, Nanno T, et al. Potentiation of warfarin by interferon. Br Med J 2000; 311: 292.CrossRefGoogle Scholar
  29. 29.
    Kramer P, Tsuru M, Cook CE, et al. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35: 416–418.PubMedCrossRefGoogle Scholar
  30. 30.
    Dorr RT. Interferon-alpha in malignant and viral diseases. A review. Drugs 1993; 45: 177–211.Google Scholar
  31. 31.
    Israel BC, Blouin RA, McIntyre W, et al. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229–235.PubMedCrossRefGoogle Scholar
  32. 32.
    Bell TM, Bansal AS, Shorthouse C, et al. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999; 14: 419–422.PubMedCrossRefGoogle Scholar
  33. 33.
    Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613–619.PubMedGoogle Scholar
  34. 34.
    Heller J, Musiolik J, Homrighausen A, et al. Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C. Dtsch Med Wochenschr 1996: 121: 1179–1183.PubMedCrossRefGoogle Scholar
  35. 35.
    Di Bisceglie AM, Shindo M, Fong TL, et al. Pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649–654.PubMedCrossRefGoogle Scholar
  36. 36.
    Di Bisceglie AM, Bacon BR, Kleiner DE, et al. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994• 21• 1109–1112Google Scholar
  37. 37.
    Fiel MI, Schiano TD, Guido M, et al. Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin. Am J Clin Pathol 2000; 113: 35–39.SGoogle Scholar
  38. 38.
    Maddrey WC. Safety of combination interferon-alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19: 67–75.PubMedGoogle Scholar
  39. 39.
    Bonkovsky HL, Stefancyk D, Tortorelli K, et al. Comparative effects of different doses of ribavirin (600 vs. 1000–1200 mg per day) plus interferon alpha-2b for therapy of chronic hepatitis C: results of a controlled, randomized trial, submitted, 2000.Google Scholar
  40. 40.
    Wong W-M, Wu P-C, Yuen M-F, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatologv 2000; 31: 201–206.CrossRefGoogle Scholar
  41. 41.
    Hanna GJ, Hirsch MS. Antiretroviral therapy of human immunodeficiency virus infection. In: Principles and Practice of Infectious Diseases (Mandell GL, Bennett JE, Dolin R, eds.), 5th ed. Philadelphia: Churchill Livingstone, 2000, pp. 1479–1499.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Ajay Batra
  • Richard W. Lambrecht
  • Herbert L. Bonkovsky

There are no affiliations available

Personalised recommendations